Raymond James downgraded AirSculpt Technologies to Market Perform from Outperform without a price target. AirSculpt’s Q1 results fell below expectations, with revenue and adjusted EBITDA allow below consensus estimates on a 10% year over year same-store case volume decline as management noted weakness in the low-end consumer, the analyst tells investors in a research note. While the valuation looks attractive relative to other healthcare services providers, the valuation is less relevant until there is more consistent execution and stabilization in the macro backdrop and same-store volumes, Raymond James argues.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AIRS:
- AirSculpt Technologies downgraded at Raymond James following ‘another miss’
- AirSculpt Technologies downgraded to Market Perform from Outperform at Raymond James
- AirSculpt Technologies maintains 2024 revenue view of $220M, consensus $219.33M
- AirSculpt Technologies reports Q1 adjusted EPS 3c, consensus (2c)
- AirSculpt Technologies Reports for First Quarter Earnings